Cellebrite DI (CLBT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellebrite DI reports a robust start to 2024 with a 27% year-over-year increase in Annual Recurring Revenue (ARR) hitting $331.8 million, and a 26% surge in Q1 revenue amounting to $89.6 million, primarily driven by a significant 29% growth in subscription revenue. The company also notes a solid adjusted EBITDA of $17.6 million, attributing its strong performance to global business expansion and the successful market adoption of its new Inseyets digital forensics software.
For further insights into CLBT stock, check out TipRanks’ Stock Analysis page.